Global registry for mitochondrial disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to create a comprehensive global registry for mitochondrial disorders, harmonizing existing national registries to enable worldwide participation. It focuses on understanding the natural history of mitochondrial diseases, which will inform the design of clinical trials and the definition of outcome measures. The study is part of the EU-financed GENOMIT project, coordinated by Dr. Holger Prokisch at Technische Universität München. It also ensures compliance with national ethics and data protection regulations while encouraging the inclusion of additional networks and countries.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* suspected or confirmed mitochondrial disease
* willingness to participate

Exclusion Criteria:

* unwillingness to participate

Where it's running

• Medical University Innsbruck, Department of Pediatrics
  Innsbruck, Austria Recruiting
• Salzburger Landeskliniken, SALK, Paracelsus Medizinische Privatuniversität
  Salzburg, Austria Recruiting
• Department of Neurology, Klinikum Rechts der Isar, Technical University Munich
  Munich, Bavaria, Germany Recruiting
• Charité Virchow Klinikum, Klinik für Pädiatrie m. S. Neurologie
  Berlin, Germany Recruiting
• Universität Bonn, Klinik und Poliklinik für Neurologie
  Bonn, Germany Recruiting
• Universitätsklinikum Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin
  Cologne, Germany Recruiting

Study contacts

• Principal investigator: Thomas Klopstock, Prof. Dr. — LMU Klinikum, Munich
• Study coordinator: Boriana Büchner, Dr.
• Email: boriana.buechner@med.uni-muenchen.de
• Phone: +49 89 4400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with rare diseases

  This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.

  Recruiting Sanford Health · Sioux Falls, South Dakota · NCT01793168

• Transplantation of MNV-201 for treating Pearson Syndrome in children

  This study is testing a new cell therapy called MNV-201 to see if it can help children with Pearson Syndrome feel better and manage their symptoms.

  Recruiting Phase 2 Minovia Therapeutics Ltd. · Ramat Gan, Israel · NCT06017869

• Effects of passive exercise on mitochondrial diseases

  This study is testing how different types of exercise, including passive exercise, affect people with mitochondrial diseases compared to healthy individuals.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05569122

• Measuring oxygen levels in muscle for mitochondrial myopathy

  This study is testing a new device that measures oxygen levels in muscles during exercise to see if it can help understand how mitochondrial myopathy affects patients and improve future treatments.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT04086329

• Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

  Researchers will look at how γδ T cells behave in severely ill patients, including those with sepsis, to see how their metabolism and function change.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Outside of the US · NCT07680816

• MNGIE Natural History Study

  Researchers are collecting anonymized patient information to see how MNGIE progresses over time and how it affects people living with the condition.

  Recruiting University of Cambridge · Cambridge · NCT07627217

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.